Baxter International dividend history

Baxter International's dividend was $0.520 a share in fiscal 2025, down 50.0% on the year before.

Dividends, buybacks and capital spending

Dividends (TTM): $102M
Diluted share count: +0.7%; year over year
Total shareholder yield: 0.8%; dividends 0.8% + buybacks 0.0% of market value
R&D spending: 4.5%; of revenue
Sales & admin spending: 25.4%; of revenue
Days sales outstanding: 56 days; receivables vs revenue

Dividends by fiscal year

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Baxter International: dividends by fiscal year, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMSept 2026
Dividend per share	$1.07	$1.18	$1.26	$1.57	$1.92	$2.05	$1.27	$0.510	$0.610	$0.730	$0.850	$0.955	$1.08	$1.15	$1.16	$1.04	$0.520	—
Dividend per share growth	—	+10.3%	+7.2%	+24.1%	+22.3%	+6.8%	−38.0%	−59.8%	+19.6%	+19.7%	+16.4%	+12.4%	+13.6%	+6.0%	+0.9%	−10.3%	−50.0%	—
Dividends paid	632	688	709	804	1,023	1,095	910	268	315	376	423	473	530	573	586	590	348	102
Share buybacks	1,216	1,453	1,583	1,480	913	550	—	292	564	2,452	1,270	500	600	32	0	0	—	—
Dividends ÷ net income	28.7%	48.5%	31.9%	34.6%	50.8%	43.9%	94.0%	5.4%	52.3%	24.3%	42.3%	42.9%	41.3%	—	22.1%	—	—	—

Dividend per share is the amount declared for the fiscal year as stated in the company's filings (including any special dividend), restated for stock splits and checked against the cash dividends paid. Dividends paid and buybacks are cash amounts; the last-twelve-months column can include an extra payment when a quarter-end date moves.

Compare with peers

Head to head: ALC vs BAX BAX vs ZBH

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Baxter International's SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Baxter International.